METT5D1 Activators
METT5D1 can harness various intracellular pathways to modulate the protein's activity. ForskolinChemical activators of METT5D1 utilize diverse molecular mechanisms to facilitate the protein's functional activity within the cell. Forskolin operates by directly stimulating adenylate cyclase, which escalates the levels of cyclic AMP (cAMP) within the cell. This surge in cAMP activates protein kinase A (PKA), which is known to phosphorylate METT5D1, thereby potentially enhancing its functional activity. Similarly, PGE1 and Isoproterenol both function by elevating intracellular cAMP levels, albeit through different receptors and mechanisms. PGE1 does so by binding to its specific G-protein-coupled receptor, while Isoproterenol acts as a β-adrenergic agonist, again leading to the activation of PKA that may subsequently phosphorylate METT5D1.
In parallel, certain chemicals prevent the breakdown of cAMP, thus indirectly contributing to the activation of PKA and subsequent phosphorylation of METT5D1. IBMX, a nonspecific inhibitor of phosphodiesterases, Rolipram, and Cilostamide, which are more selective inhibitors of PDE4 and PDE3 respectively, all increase cAMP levels by impeding its degradation. Furthermore, Terbutaline, a β2-adrenergic agonist, and Zaprinast, a selective inhibitor of PDE5, also boost intracellular cAMP, which is a prerequisite for PKA activation and the resulting phosphorylation of METT5D1. On a slightly different note, H-89, although a potent inhibitor of PKA, is used at sub-inhibitory concentrations to chronically activate PKA through a feedback mechanism, and Anisomycin activates stress-activated protein kinases (SAPKs) which can also lead to the phosphorylation of METT5D1. Lastly, 8-Br-cAMP and Sp-5,6-DCl-cBIMPS, which are cAMP analogs and activators, respectively, directly activate PKA, streamlining the process that leads to the phosphorylation and the consequent activation of METT5D1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, enzymes that degrade cAMP. By preventing cAMP breakdown, IBMX indirectly raises cAMP levels, which can activate PKA that, in turn, may phosphorylate and activate METT5D1. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) binds to its G-protein-coupled receptor, leading to increased intracellular cAMP levels. This rise in cAMP is likely to activate PKA, which can phosphorylate METT5D1, potentially enhancing its activation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a β-adrenergic agonist that increases intracellular levels of cAMP by activating adenylate cyclase. The subsequent activation of PKA could result in phosphorylation and activation of METT5D1. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that activates stress-activated protein kinases (SAPKs). These kinases can activate a variety of downstream proteins including METT5D1 through phosphorylation. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can lead to phosphorylation and functional activation of METT5D1. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
Sp-5,6-DCl-cBIMPS is a potent and selective activator of cAMP-dependent PKA. PKA can phosphorylate METT5D1, which may result in its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which increases cAMP levels by preventing its breakdown. Elevated cAMP may activate PKA, which could phosphorylate and activate METT5D1. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of PDE3, which increases cAMP levels by preventing its breakdown. The resultant increase in cAMP may activate PKA, potentially leading to phosphorylation and activation of METT5D1. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline is a β2-adrenergic agonist that can raise intracellular cAMP levels by activating adenylate cyclase. This increase in cAMP can activate PKA, which in turn may phosphorylate and activate METT5D1. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of PDE5, which increases cAMP and cGMP by preventing their breakdown. The increase in cAMP can activate PKA, potentially leading to phosphorylation and functional activation of METT5D1. | ||||||